NYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis $84.84 +0.23 (+0.27%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$84.90 +0.07 (+0.08%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Globus Medical Stock (NYSE:GMED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Globus Medical alerts:Sign Up Key Stats Today's Range$84.16▼$86.0250-Day Range$75.65▼$96.6852-Week Range$51.79▼$101.40Volume1.81 million shsAverage Volume1.81 million shsMarket Capitalization$11.52 billionP/E Ratio19.73Dividend YieldN/APrice Target$106.36Consensus RatingModerate Buy Company Overview Globus Medical, Inc. (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes. In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room. The ExcelsiusGPS® robotic guidance system, for example, integrates real-time imaging with robotic arm technology to enable surgeons to perform complex procedures with greater accuracy. The company also offers an array of trauma and orthopaedic solutions, such as bone graft substitutes and joint reconstruction implants, to address a broad spectrum of musculoskeletal conditions. Globus Medical serves surgeons and patients across North America, Europe, Asia, Latin America and the Middle East through a combination of direct sales and distribution partnerships. Under the leadership of founder and Executive Chairman David C. Paul and President and Chief Executive Officer Glenn J. Shapiro, the company has built a global commercial infrastructure and invested in research and development to drive innovation. Its commitment to surgical education and customer support further reinforces its position in the competitive medical device landscape.AI Generated. May Contain Errors. Read More Globus Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreGMED MarketRank™: Globus Medical scored higher than 96% of companies evaluated by MarketBeat, and ranked 17th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 2 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialGlobus Medical has a consensus price target of $106.36, representing about 25.4% upside from its current price of $84.84.Amount of Analyst CoverageGlobus Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Globus Medical's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.75% Earnings GrowthEarnings for Globus Medical are expected to grow by 6.75% in the coming year, from $4.74 to $5.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 19.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 19.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.06.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Globus Medical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.83% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 3.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Globus Medical has recently decreased by 5.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.67 News SentimentGlobus Medical has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Globus Medical this week, compared to 6 articles on an average week.Search Interest22 people have searched for GMED on MarketBeat in the last 30 days. This is an increase of 214% compared to the previous 30 days.MarketBeat Follows7 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,890,000.00 in company stock.Percentage Held by Insiders18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Globus Medical's insider trading history. Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMED Stock News HeadlinesGlobus Medical Uses Generative AI And M&A To Reshape Growth ProfileMay 22 at 3:15 PM | finance.yahoo.comBull of the Day: Globus Medical (GMED)May 21 at 1:34 AM | theglobeandmail.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”May 20, 2026 | insidermonkey.comGlobus Medical EPS Surges as Margins ExpandMay 19, 2026 | tipranks.comNeedham Raises its Price Target on Globus Medical (GMED)May 19, 2026 | insidermonkey.comGlobus Medical Inc Class AMay 17, 2026 | cnn.com5 must-read analyst questions from Globus Medical’s Q1 earnings callMay 14, 2026 | msn.comSee More Headlines GMED Stock Analysis - Frequently Asked Questions How have GMED shares performed this year? Globus Medical's stock was trading at $87.39 at the start of the year. Since then, GMED stock has decreased by 2.9% and is now trading at $84.8370. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) posted its earnings results on Thursday, May, 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.20. The company's revenue was up 27.0% on a year-over-year basis. Read the conference call transcript. Is Globus Medical buying back stock? Globus Medical's Board of Directors approved a share repurchase plan on Thursday, May 15th 2025, which authorizes the company to repurchase $500,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 6.3% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued. When did Globus Medical IPO? Globus Medical (GMED) raised $200 million in an initial public offering (IPO) on Friday, August 3rd 2012. The company issued 11,764,705 shares at $16.00-$18.00 per share. Who are Globus Medical's major shareholders? Globus Medical's top institutional shareholders include Janus Henderson Group PLC (5.62%), Sculptor Capital LP (2.25%), Dimensional Fund Advisors LP (1.31%) and Boston Trust Walden Corp (0.93%). Insiders that own company stock include David D Davidar, Ann D Rhoads, Leslie V Norwalk, Dan Lemaitre, Daniel T Scavilla, Keith W Pfeil, Kelly Huller, Kyle Kline and Stephen T Zarrilli. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, GMED's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNYSE:GMED CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees6,000Year Founded2003Price Target and Rating Average Price Target for Globus Medical$106.36 High Price Target$123.00 Low Price Target$64.00 Potential Upside/Downside+25.4%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$4.30 Trailing P/E Ratio19.73 Forward P/E Ratio17.90 P/E Growth1.75Net Income$537.87 million Net Margins18.92% Pretax Margin21.24% Return on Equity13.46% Return on Assets11.65% Debt Debt-to-Equity RatioN/A Current Ratio4.56 Quick Ratio2.95 Sales & Book Value Annual Sales$2.94 billion Price / Sales3.92 Cash Flow$6.28 per share Price / Cash Flow13.50 Book Value$34.86 per share Price / Book2.43Miscellaneous Outstanding Shares135,740,000Free Float110,795,000Market Cap$11.52 billion OptionableOptionable Beta1.00 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:GMED) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
